22 results about "Chemotherapy combinations" patented technology

The present invention relates to a combination therapy regimen of a FAK inhibitor (FAKi) and a FOLFIRINOX chemotherapy regimen, and to the use of this therapy regimen as a means of treating cancer in patients who require cancer treatment, particularly in patients with fibrous cancers / tumors such as pancreatic cancer. Accordingly, the first embodiment provides a method for treating cancer in a subject who requires cancer treatment, comprising administering a combination of a FAK inhibitor (FAKi) and a FOLFIRINOX chemotherapy regimen.

The present invention relates to methods of treating previously untreated diffuse large B-cell lymphoma (DLBCL), which is defined as high risk according to circulating tumor DNA (ctDNA), by administering gphentumab and in combination with chemotherapy.

To provide a combination chemotherapy exhibiting a large therapeutic effect on cancer, especially bladder cancer.SOLUTION: There is provided a first chemotherapeutic agent and a second chemotherapeutic agent for use in the treatment of cancer, wherein the second chemotherapeutic agent comprises a biologically active complex having anti-tumour activity, wherein the biologically active complex consists of a peptide of at least 10 amino acids comprising an alpha-helical structure and oleic acid or oleate in a ratio of at least 3 oleic acid or oleate molecules per peptide molecule. Provided are either a first chemotherapeutic agent or a second chemotherapeutic agent for use in cancer therapy, for use in conjunction with other chemotherapeutic agents, pharmaceutical compositions related thereto, and methods of treatment.SELECTED DRAWING: None

The invention discloses an adverse reaction dynamic monitoring and follow-up management system after chemotherapy, and relates to the technical field of data processing, and the system comprises an acquisition module which determines a to-be-monitored symptom and a corresponding target part according to a chemotherapy regimen of a patient, and receives an image of the target part; the recognition module carries out registration on the part partition map and the target part image, a reaction partition with an abnormal color block area is determined, and color block positioning points are marked; the analysis module generates a positioning acquisition frame according to the part partition to which the color block positioning points belong, receives the review part image, cuts the target part image and the review part image based on the positioning acquisition frame, and determines the point location diffusion amount; and the decision-making module determines a follow-up visit mode according to the point location diffusion amount and the partition position of the reaction partition. The patient is guided to review and shoot the same position through the positioning collection frame, the follow-up visit mode is determined in combination with the partition positions, and the accuracy of follow-up visit decision is improved.

The invention discloses an AML chemotherapy regimen sharing method and system based on distributed processing, and belongs to the technical field of medical information. The method comprises the following steps: acquiring clinical data related to an AML chemotherapy regimen, including patient information, pathological indexes and iconography data, performing preprocessing and semantic annotation, and generating a semantic clinical data unit with a distributed identifier; registering the identifier, the metadata and the digital signature to a distributed account book network maintained by multiple mechanisms; receiving a query request based on the semantic tag and the metadata, and matching a data unit in an account book network through a semantic engine; and after verifying the authority of the requester, transmitting a data load or executing a distributed computing task of which the data cannot be out of the domain through the secure channel. The problems of privacy security, cross-mechanism interoperation and credible authentication in clinical data sharing are effectively solved, and an efficient and reliable data collaboration platform is provided for AML diagnosis and treatment research.

Extranodal natural killer / T-cell lymphoma (ENKTCL) is an aggressive haematological malignancy. The treatment of ENKTCL is dependent on the extent of the tumor. However the use of L-asparaginase-containing regimens obtained impressive outcomes as induction or salvage treatment for ENKTCL. Although more than 70% of early-stage patients can achieve long-term survival, patients with advanced-stage disease had extremely poor prognosis even after asparaginase-based chemotherapy regimens. There is thus a medical need for improving the treatment of ENKTCL with L-asparaginase. Now the inventors demonstrate the interest of the use of L-asparaginase in combination with a ferroptosis inducer for the treatment of ENKTCL. In particular, combination of APR-246 and Erwinase R has synergistic effects in KHYG-1 cells. The present invention thus relates to the use of a L-asparaginase in combination with a ferroptosis inducer for the treatment of ENKTCL.

Methods of treating gastric cancer or gastroesophageal junction cancer in subjects are described. The methods may comprise administering an anti-FGFR2b antibody to the subject. The methods may further comprise administering a chemotherapy regimen comprising (a) oxaliplatin and capecitabine; or (b) oxaliplatin and S-1 to the subject.

The invention belongs to the technical field of application of traditional Chinese medicine preparations, and discloses application of Jinshuiliujun decoction in preparation of a medicine for treating EGFR sensitive mutation non-small cell lung cancer, the medicine is used for being applied in combination with chemotherapy, a classic traditional Chinese medicine compound is combined with a modern chemotherapy regimen, and when a patient suffering from IIIb / IV-stage EGFR sensitive mutation is treated, the curative effect is good, and the curative effect is good. The pharmaceutical composition shows clear synergistic interaction and toxicity reduction effects, and the specific performance is as follows: the median progression-free lifetime of a patient is obviously prolonged; the traditional Chinese medicine syndromes such as cough and weakness are improved; the immunologic function is effectively regulated, and the CD4 + / CD8 + ratio is increased; the negative emotion score of the patient is reduced; the adverse reaction incidence rate of chemotherapy is not increased; a brand new traditional Chinese and western medicine combined treatment scheme is provided for the specific lung cancer subtype, and the curative effect and life quality are improved.

The present disclosure relates to using ivonescimab, an anti-VEGF x anti-PD-1 bispecific antibody, optionally in combination with other therapies, to treat cancers. Disclosed embodiments include: ivonescimab or ivonescimab in combination with ligufalimab to treat head and neck squamous cell carcinoma (e.g., PD-L1 positive recurrent or metastatic head and neck squamous cell carcinoma); perioperative ivonescimab or ivonescimab in combination with chemotherapy to treat resectable non-small cell lung cancer; ivonescimab in combination with chemotherapy or in combination with ligufalimab and chemotherapy to treat colorectal cancer (e.g., recurrent or metastatic colorectal cancer); ivonescimab to treat advanced non-small cell lung cancer; and ivonescimab in combination with chemotherapy to treat locally advanced unresectable or metastatic triple-negative breast cancer.

The invention discloses a diagnosis and treatment target device for cytophagic lymphocytosis. The device comprises a detection module, a detection module and a control module, wherein the detection module is used for detecting the expression quantity of four genes, namely CCR2, CDKN1A, TNFSF10 and TP53INP2 in a patient sample of a current patient; the detection module is used for detecting the expression quantity of four genes, namely CCR2, CDKN1A, TNFSF10 and TP53INP2; the analysis module is used for carrying out difference analysis on the expression quantity and the expression quantity of a healthy control group to obtain a molecular characteristic spectrum related to the HLH; the diagnosis typing treatment module is used for performing diagnosis typing on the current patient according to a difference mode of the molecular characteristic spectrum and treating according to a diagnosis typing result, so that serious treatment toxicity such as myelosuppression and liver and kidney injury of a traditional chemotherapy regimen can be reduced, the safety and effectiveness of clinical treatment of the patient are improved, and higher specificity and accuracy are achieved; a foundation is laid for developing a novel diagnostic tool, and a direct and feasible candidate scheme and a theoretical basis are provided for developing a high-efficiency and low-toxicity HLH new therapy.

A system for remote assessment of clinical response and dynamic optimization of the chemotherapy regimen in oncology, consisting of: a device for clinical assessment of patient response, designed as a physical machine structure with a housing for use on the body or at the bedside; a housing-mounted physiological sensor unit configured to record continuous or periodic measurements of heart rate, heart rate variability, respiratory rate, peripheral oxygen saturation, body temperature, physical activity and sleep-related parameters of an oncology patient during chemotherapy; a biochemical sensor unit integrated into the housing, configured to detect biochemical indicators related to response to chemotherapy and toxicity, including inflammatory markers, metabolic indicators, hematological trends or drug-related metabolites; a patient interaction unit configured to receive symptom data reported by the patient, corresponding to treatment tolerability and functional status; an embedded processing unit that is operationally connected to the physiological sensor unit, the biochemical sensor unit, and the patient interaction unit, and is configured to perform signal conditioning, temporal alignment, data integrity verification, and encryption of the acquired patient data; a communication unit that is operationally connected to the embedded processing unit and configured to transmit the processed patient data to a remote processing infrastructure using secure communication protocols; a remote processing system comprising at least one processing unit and a storage unit for storing executable instructions, wherein the processing unit is configured to aggregate longitudinal patient data across chemotherapy cycles, analyze correlations between recorded physiological data, biochemical indicators, patient-reported outcomes, and parameters of chemotherapy administration, and calculate a clinical assessment of response; and A system for interacting with physicians, configured to display the results of the clinical response assessment and generate recommendations for optimizing the chemotherapy regimen, which are subject to review and approval by the physician.

The addition of a selective, fast-acting, short half-life CDK 4 / 6 inhibitor in a very specific dosage regimen to the combination of chemotherapy with a checkpoint inhibitor provides superior results in the treatment of a tumor or cancer. The unexpected discovery is that the short pulsatile specifically-timed administration of a selective, fast-acting, short half-life CDK 4 / 6 inhibitor during administration of the chemotherapy portion of the triple combination therapy has a profound effect on the immune cells in the cancer microenvironment.

This application relates to uses of antibodies against fibroblast growth factor receptor 2 (FGFR2), including antibodies against the FGFR2 isoform FGFR2-IIIb (also known as FGFR2b), in treatment of certain cancers in combinations with mFOLFOX6 chemotherapy.

This invention relates to a combination chemotherapy drug for solid tumors, comprising any clinically used chemotherapy drug combined with a mitochondrial extract to form the active pharmaceutical ingredient, wherein the mitochondrial extract and the clinically used chemotherapy drug are each an independent drug delivery unit. Experiments of this invention have demonstrated that the combined use of the mitochondrial extract and the chemotherapy drug effectively enhances the drug's efficacy compared to using the chemotherapy drug alone, thereby improving the therapeutic effect of chemotherapy for solid tumors.

The disclosure provides a method of treating a human subject afflicted with lung cancer with a lymphocyte activation gene-3 (LAG-3) antagonist. In some aspects, the method comprises combination of the LAG-3 antagonist with an additional therapeutic agent (e.g., a programmed death-1 pathway inhibitor) and / or anti-cancer therapy (e.g., chemotherapy such as a platinum doublet chemotherapy).

This disclosure provides a method of preventing, alleviating or treating a condition (i.e., neutropenia) in a subject in need thereof, the condition characterized by compromised white blood cell production in the subject. The method includes administering to the subject a therapeutically effective amount of a protein complex on the same day as a chemotherapy regimen, wherein the protein complex is a modified human granulocyte-colony stimulating factor (hG-CSF) covalently linked to an immunoglobulin Fc region via a non-peptidyl polymer. The non-peptidyl polymer is site-specifically linked to an N-terminus of the immunoglobulin Fc region, and the modified hG-CSF comprises substitutions in at least one of Cys17 and Pro65.

This invention provides an immunomodulator for use in the treatment, reduction, inhibition or control of cancer subject, wherein the subject is clinically classified as having a performance status of 1-, 2, 3 or 4 according to the ECOG Scale, or classified as not being of an age and / or not being sufficiently fit to tolerate two or more chemotherapy regimens. The invention also describes the use of one or more additional anticancer treatments or agents as well as protocols and dosage regimens for use.

Provided herein are methods of treating cancer by administering a combination therapy comprising a KRAS G12D inhibitor, folinic acid, 5-fluorouracil, irinotecan, and oxaliplatin.

The invention provides an AML chemotherapy regimen bone marrow morphology prediction method and device based on bone marrow next-generation sequencing. The method comprises the following steps: acquiring bone marrow next-generation sequencing data of an AML patient before treatment, extracting an associated mutant gene list from the bone marrow next-generation sequencing data, then mapping the associated mutant gene list to an AML field knowledge graph, acquiring each target node successfully mapped by the associated mutant gene list in the AML field knowledge graph, and determining the target node according to the acquired target node. Feature settlement corresponding to each target node is extracted from the AML domain knowledge graph, the feature settlement is a connected sub-graph which takes the target node as the center and is determined according to a predefined topology rule, the feature settlement corresponding to each target node is input into a bone marrow morphology prediction model, and a bone marrow morphology prediction model is obtained. The method solves the problem that in the prior art, the bone marrow morphology cannot be predicted before chemotherapy, so that an original refractory patient cannot be recognized in a prospective manner.

The present application relates to a kind of recombinant complement protein and the application in the preparation of anti-leukemia drugs, belong to biological medicine technical field;The present application discloses that single drug treatment, i.e. injection recombinant C1QBP protein has significant effect in the treatment of acute leukemia, can significantly inhibit the proliferation of leukemia cells in hematopoietic system bone marrow, spleen, peripheral blood, while inhibiting the infiltration of leukemia cells in extramedullary organs (skin, etc.), thereby reducing the whole body tumor load, significantly prolonging the survival period of leukemia mouse.Recombinant C1QBP protein is combined with clinical first-line chemotherapy regimen, has synergistic effect, compared with single use chemotherapy drug has stronger effect of inhibiting the proliferation of leukemia cells, can significantly prolong the survival period of leukemia mouse, has played the effect of attenuated and synergistic effect.The present application first proves that complement C1Q binding protein has the effect of treating leukemia, and provides preparation method and combined drug regimen, has higher clinical conversion prospect and application value.

The invention discloses an ovarian cancer chemotherapy regimen recommendation method based on drug sensitivity prediction, and relates to the field of data analysis. The method comprises the steps that a drug sensitivity general recognition model cluster is established according to historical scheme records of ovarian cancer chemotherapy, and the drug sensitivity general recognition model cluster comprises a metabolic kinetics meta-model, a side effect intensity meta-model and a recovery degree-side effect violation meta-model which are cascaded; static feature information and historical chemotherapy records of a target patient are obtained, the drug sensitivity general recognition model cluster is subjected to rapid adaptation, and a sensitivity specialized model cluster of the target patient is obtained; and based on the sensitivity specialized model cluster, performing optimization decision on a chemotherapy regimen, and outputting a recommended chemotherapy regimen. According to the invention, pertinence and accuracy of ovarian cancer chemotherapy regimen recommendation are effectively improved.